Singh discusses his analysis of all 3 parts of the NODE-301 phase 3 trial, investigating the recently approved CBB’s potential risk of hypotension.
Narendra Singh, MD
Advertisement
Narendra Singh, MD, is an assistant professor at Mercer University Atlanta Campus and the director of clinical research at NSC Cardiology.
Articles by Narendra Singh, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
4
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
5